Pioneering Research on AHSCT/HSCT for Multiple Sclerosis and Autoimmune Diseases

Compilation of Published Research on HSCT in Global Medical Journals

Autologous Hematopoietic Stem Cell Transplantation (AHSCT), commonly referred to as HSCT, is rapidly reshaping the conversation around treatment for Multiple Sclerosis (MS) and other stubborn autoimmune conditions. Unlike conventional therapies that only manage symptoms or slow progression, HSCT takes a bold step—it essentially “resets” the immune system. For patients who have exhausted traditional options, this offers something rare: genuine hope.

In the last decade, clinical trials from leading research canters across the globe have reported striking outcomes—fewer relapses, improved day-to-day function, and, for some, years of sustained remission.

We have compiled below a curated list of key research papers and clinical trials based on recent searches from PubMed and ClinicalTrials.gov. This is not an exhaustive list (as there are hundreds of publications), but it focuses on prominent, recent (up to 2025), and influential studies. For full access, many PubMed links lead to abstracts; full texts may require institutional access or purchase.

Broad Conclusions from Research and Clinical Trials on HSCT/AHSCT for Multiple Sclerosis and other Auto immune conditions.

Hematopoietic Stem Cell Transplantation (HSCT), particularly its autologous form (AHSCT), represents a high-intensity, immune-reprogramming therapy for multiple sclerosis (MS). In AHSCT, a patient’s own hematopoietic stem cells are harvested, followed by myeloablative or non-myeloablative chemotherapy (e.g., cyclophosphamide-based regimens) to deplete autoreactive immune cells, and then reinfusion of the stem cells to rebuild a tolerant immune system.

This “reset” aims to halt inflammatory activity in aggressive relapsing-remitting MS (RRMS), where disease-modifying therapies (DMTs) like ocrelizumab or natalizumab fail. Since the first MS AHSCT case in 1995, over 3,000 procedures have been performed globally, with accumulating evidence from meta-analyses, cohort studies, and randomized trials supporting its role as a one-time, potentially curative option for select patients.

Efficacy of HSCT proven : Halting Disease Activity and Improving Disability

AHSCT offers transformative potential for aggressive RRMS, with meta-analytic evidence of durable remissions outperforming DMTs, at the cost of manageable short-term risks. Long-term data affirm its role in immune reset, but progressive MS remains challenging. As of 2025, EBMT-endorsed protocols are expanding access, with ongoing trials addressing equity and optimization. Recent meta-analyses and reviews consistently demonstrate AHSCT’s superior efficacy over standard DMTs in highly active RRMS, with high rates of

Long-Term Outcomes: Durability and Quality of Life

Follow-up data (5–15 years) from registries like EBMT and ASTCT highlight durable remissions, though ~20–30% experience late relapses or progression.

Survival and Remission Rates:

• Progression-free survival: 80% at 10 years in early RRMS; drops to 50–60% in progressive subtypes.
• Danish cohort (2023, n=81 aggressive RRMS): 92% relapse-free at 5 years; EDSS stable/improved in 75%.
• UK experience (2025, n=364): 70% NEDA at 7 years; factors for better outcomes: age <35, disease duration <5 years, pre-AHSCT EDSS <4.

Younger patients with shorter disease duration and fewer prior DMTs fare best, with some achieving 15+ years of remission.

Safety and Risks: Balancing Intensity with Modern Protocols HSCT’s risks have declined with refined conditioning (e.g., low-dose cyclophosphamide + ATG) and supportive care, but it’s not risk-free. Treatment-related mortality (TRM) is now <1% in experienced centers. Risk Mitigation: Prior rituximab exposure protects against post-AHSCT inflammation. Neuropsychological reviews (2024) show cognitive stability/improvement in 80%, with minimal decline.

 Research Papers on AHSCT/HSCT for Other Autoimmune Diseases

These cover a range of conditions like systemic sclerosis, lupus, and Crohn’s disease, excluding MS.

HSCT (Hematopoietic Stem Cell Transplantation) for Multiple Sclerosis is now available at JCI-USA accredited World Class Hospital in India at most affordable cost.

HSCT attempts to “reboot” the faulty immune system, which is responsible for damaging the brain and spinal cord in MS. At present the total cost of HSCT at major centres like Mexico and Russia cost more than 100,000 US Dollars including travel and stay. At world class HSCT Hospital India HSCT costs about 30,000 US Dollars all inclusive. Please click this link to know more about world’s most affordable HSCT treatment Please click this link to know more about world’s most affordable HSCT treatment

Why you should choose HSCT Hospital India for HSCT ?

• HSCT Hospital India is one of the finest private hospitals in India and Accredited by JCIUSA. Most Affordable, 30,000 US $ HSCT package includes complete treatment cost for 30 days inhospital stay in a deluxe private room, Doctors Fee, Tests and Consultations, Medicines, Consumables, Neuro-Physiotherapy and also Food and Laundry for both the patient and the attendant, Airport Transfers etc. Large number of MS patients from Europe, America and Australia already treated successfully. Click here to know more
• Complete 30 day HSCT done in hospital. Private deluxe rooms are very well served for patient and attendant’s comfort and equipped with HEPA Filter with Triple Level Air Filtration. No outside hospital stay avoids risk of infection, 24 x 7 nursing care and best medical attention. Advanced HSCT for MS protocol used does not require any further chemo/ treatment after leaving the hospital. Click here to get complete details
• International and Globally Renowned Accreditations – HSCT Hospital India is accredited by the Joint Commission International, USA, National Accreditation Board for Hospitals and Healthcare Providers (NABH), and National Accreditation Board for Laboratories (NABL) for processes and high-quality patient care.
• Large number of MS patients from Europe, America and Australia have already been treated successfully at HSCT Hospital India. Click here to watch patient testimonial videos